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was highest among patients who were using oral chemotherapy agents (34.1%). The 
number of non-adherent behaviors was significantly associated with a decrease 
in functional well-being (FWB; b= -1.40), FACT-G total score (b= -3.01), FACT-B total 
score (b= -3.92), and FACT trial outcome index (FACT-TOI; b= -2.98) (all p< .05). These 
relationships were stronger when focusing on respondents who were using an oral 
chemotherapy agent (n= 44) (bs= -3.14, -7.37, -6.11, -8.63 for FWB, FACT-G, FACT-B, and 
FACT-TOI, respectively). ConClusions: Approximately a third reported engaging 
in non-adherent behavior. These behaviors were associated with significant decre-
ments in health status, suggesting improvements in adherence could correspond 
to quality of life benefits to the patient.
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objeCtives: Utility values used in economic evaluations of new products reflect 
the strength of preference for the health related quality of life (HRQL) of a given 
health state. These can be captured using the time trade-off (TTO) methodology. 
The aim of this study was to elicit societal utility values for states related to chronic 
lymphocytic leukemia (CLL). Methods: Nine health states were developed fol-
lowing a literature review, interviews with patients (n= 6) and clinicians (n= 5), and 
review by lay members of the public (cognitive debriefing; n= 5). These health states 
were: progression free survival (PFS) on initial intravenous (IV) therapy; PFS on ini-
tial oral therapy; PFS on initial therapy with increased hospital visits; PFS without 
therapy; progression after 1st line therapy; PFS on 2nd line therapy; PFS without 2nd 
line therapy (post 2nd line treatment, but not currently receiving therapy); further 
progression (disease progression after 2 lines of treatment); and relapsed lines of 
treatment (≥ 3 lines of treatment). One hundred members of the UK general public 
valued each health state using the TTO methodology. Results: PFS states were 
the least burdensome: PFS without therapy (mean utility= 0.82); PFS on initial oral 
therapy (0.71); PFS on initial IV therapy (0.67), apart from PFS on initial therapy with 
increased hospital visits (0.55). Mean utility for disease progression after 1st line 
therapy was 0.66 and for PFS without 2nd line therapy was 0.71; further progres-
sion (0.59), PFS on 2ndline therapy (0.55), and relapsed lines of treatment (0.42) had 
greater burdens. ConClusions: The results show the weights that the general 
public place on CLL states, underlining the value in maintaining PFS for as long as 
possible. Findings also highlight the extent to which HRQL declines following first 
line progression. These findings can support the estimation of quality adjusted life 
years associated with treatments for CLL.
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objeCtives: Health-state utilities values (HSUVs) are an essential component for 
cost-utility analysis (CUA). The aim of this review was to systematically identify 
utility weights associated with advanced gastric (GC), oesophageal (OC), or gastro-
oesophageal junction (GEJ) adenocarcinoma. Methods: Embase, MEDLINE and 
Cochrane databases (accessed September 2013) were interrogated for relevant 
studies using a predefined search strategy. Studies eligible for inclusion included 
those reporting HSUVs using direct (standard gamble [SG] and time-trade-off 
[TTO]) and indirect methods (such as EuroQol 5D [EQ-5D], short-form 6D [SF-6D] 
and 15D). Results: A total of 703 publications were identified, of which eight met 
the inclusion criteria (GC, n= 2; mixed population [MP], n= 4; OC, n= 2). The most 
commonly used instrument to estimate HSUVs was the EQ-5D (n= 7): post-chem-
otherapy (GC, 0.550 [n= 1]; MP, 0.66-0.76 [n= 1]); progression-free survival (GC, 0.73 
[n= 1]); weight loss (MP, 0.52-0.69 [n= 2]); patient’s valuation of health state (OC, 
0.60-0.93 depending on stage [n= 1]); dysphagia-associated (OC, 0.39-0.82, depending 
on score [n= 1]); societal valuation of health state (OC, 0.15-0.77 [n= 1]); inoperable 
OC/GEJ (MP, 0.63 [n= 1]). One study derived utilities using the SF-6D and the 15D 
(post-chemotherapy in GC patients, 0.606 and 0.685, respectively). In two studies 
the TTO method was used to determine the following HSUVs: patient’s valuation of 
health state (OC, 0.52-0.80 depending on stage [n= 1]); societal valuation of health 
state (0.15-0.77, [n= 1]); dysphagia-associated (OC, 0.25-0.86, depending on score 
[n= 1]); inoperable OC (0.08-0.66, depending on health state [n= 1]). Only one study 
determined HSUVs for inoperable OC according to the SG method (0.08-0.78, depend-
ing on health state). ConClusions: There are limited data estimating HSUVs in 
patients with advanced GC, OC or GEJ. Comparisons are confounded by heteroge-
neity across patient and study characteristics in the identified studies. Further 
research into HSUVs associated with advanced gastric/oesophageal cancers is 
required in order to improve the evidence available for use in CUAs.
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objeCtives: To evaluate the quality of life (QoL) of CML patients using the EQ-5D-5L 
instrument by gathering the patient’s perspective of how, and to what extent, their 
therapy impacts QoL. Methods: Patients from the Huntsman Cancer Institute com-
CaNCer – Patient-reported outcomes & Patient Preference Studies
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objeCtives: Examine baseline treatment patterns and persistence among patients 
diagnosed with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal 
tumor (GIST) and treated with Stivarga® (regorafenib). Methods: Adult patients 
treated with Stivarga from 9/27/12-7/31/13 were identified from a large national 
US claims database. Patients were retained if they were continuously enrolled in 
the health plan for ≥ 6 months before the initial (index) fill (baseline period) and 
≥ 1 month after the index fill (follow-up period). Patients were required to be diag-
nosed with mCRC or GIST, be 18+ years old, and have non-missing demographic 
information. Follow-up persistence with Stivarga was identified based on a gap in 
therapy of at least 30 days. The use of chemotherapy in the baseline, the last regimen 
received before initiating Stivarga, and the amount of time between receipt of last 
chemotherapy and Stivarga initiation was identified. Results: 283 patients were 
treated with Stivarga and 235 met all inclusion criteria. Mean age was 61.6 years, 
66.4% were female, and 38.7% were Medicare Advantage patients. Mean baseline 
length was 4.2 years (median: 3.3 years). Mean follow-up length was 4.5 months. 
Baseline chemotherapy use was observed in 97.5% of patients; 89.5%, 72.9%, and 
79.9% of patients received irinotecan, oxaliplatin or bevacizumab, respectively. The 
most common regimens prior to Stivarga were FOLFIRI (12.7%), FOLFIRI+BEV (10.0%), 
and Irinotecan+Cetuximab (8.7%). On average, patients had a gap of 85 days from 
receipt of last chemotherapy until initiating Stivarga; 50% initiated within 30 days 
and 25% initiated after more than 84 days. Patients received 2.5 fills of Stivarga and 
were persistent for 69.5 days, on average. 37.5% of patients were persistent through 
the end of their follow-up. ConClusions: Most Stivarga-treated mCRC or GIST 
patients received chemotherapy in the 3 months prior to initiating Stivarga. At least 
half of patients were persistent for at least 8 weeks.
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objeCtives: To compare adherence rates to oral versus intravenous (IV) chemother-
apy regimens to treat metastatic colorectal cancer (CRC). Methods: A retrospective 
analysis was performed using the OptumInsight Oncology claims database. Patients 
aged 18 years and older, diagnosed with metastatic CRC between July 1, 2004 and 
December 31, 2010, who were insured by a commercial health plan were included. 
Adherence was assessed using the medication possession ratio (MPR), calculated 
as the proportion of days a patient was covered by their chemotherapy regimen, 
according to NCCN guidelines, from the first to the last cycle/prescription of that 
regimen. Comparisons of MPR between the groups were performed by multivariate 
logistic regression, using the threshold of MPR> 0.8 to define high adherence; and 
by multivariate linear regression treating MPR as a continuous variable. Results: 
A total of 9,964 chemotherapy regimens in cycles in 3,367 patients were analyzed. 
The most common regimens were IV FOLFOX (n= 1,710), oral capecitabine (n= 1,328), 
and IV FOLFOX+bevacizumab (n= 1,100). Overall, adherence was significantly higher 
for IV regimens (mean MPR = 0.88) versus capecitabine oral regimens (mean MPR 
= 0.80, p< 0.001). Additionally, a significantly higher proportion of patients receiv-
ing IV regimens (77%) achieved an MPR > 0.8 compared with patients receiving 
capecitabine chemotherapy (53%, p< 0.001). These differences persisted when 
stratifying by line of chemotherapy, age, and disease severity (measured using the 
weighted Charlson index). In multivariate logistic regression, oral chemotherapy 
regimens were associated with an odds ratio of 0.33 regarding achieving an MPR of 
> 0.8. Similarly, in multivariate linear regression capecitabine oral chemotherapy 
regimens were associated with a significant decrement in MPR (beta coefficient = 
-0.084, p< 0.001). ConClusions: Capecitabine oral chemotherapy regimens were 
associated with a significantly lower adherence rate compared with IV regimens in 
metastatic CRC patients. The clinical impact of the observed differences is unknown.
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objeCtives: The increasing availability of treatment options for metastatic breast 
cancer (mBC), particularly oral chemotherapy agents, has elevated the importance 
of adherence. This study sought to address the relationship between non-adherence 
and quality of life among women with mBC. Methods: A cross-sectional Internet 
survey was administered to 181 women diagnosed with mBC who had prior expe-
rience with either a taxane, paclitaxel, or docetaxel. Demographic, health history, 
treatment history (e.g., current use of chemotherapy [oral or IV], radiation therapy, 
or hormone therapy) and quality of life in the past 7 days (using the FACT-B) infor-
mation was collected. Patients were asked whether they had skipped/missed a 
dose and the reason for doing so (e.g., tolerability of side effects, reduce cost). The 
number of different non-adherence reasons was used to predict FACT-B scores using 
regression modeling, controlling for demographics and health history. Subgroup 
analyses were conducted among those using IV and oral chemotherapy agents, sep-
arately. Results: The mean age was 52.2 years and 93.9% were non-Hispanic white. 
42.0% and 24.3% of respondents were currently using an IV and oral chemotherapy 
agent, respectively. Across all treatments, 34.8% of respondents reported engaging 
in non-adherent behavior. Aside from hormone therapy (43.0%), non-adherence 
